Literature DB >> 23673011

Neuromelanin MRI in a family with mitochondrial parkinsonism harboring a Y955C mutation in POLG1.

Masako Mukai1, Keizo Sugaya, Ichiro Yabe, Yu-ichi Goto, Fusako Yokochi, Kazuhito Miyamoto, Huaying Cai, Hidenao Sasaki, Shiro Matsubara.   

Abstract

BACKGROUND: Progressive external ophthalmoplegia (PEO) and parkinsonism can be caused by genetic mutations that affect mitochondrial DNA (mtDNA) maintenance. We characterized parkinsonism in a family with dominantly inherited PEO.
METHODS: We conducted clinical, histological and genetic analyses on two affected members suffering from PEO and parkinsonism, and reviewed the cases in the literature. To clarify parkinsonism related to multiple mtDNA deletions, we used 3-T neuromelanin magnetic resonance imaging (MRI) to assess signal changes in the substantia nigra (SN) and locus ceruleus (LC) in our patients, and compared the results to those observed in idiopathic Parkinson's disease (iPD) (n = 35).
RESULTS: We report the first case of a Japanese family harboring a heterozygous p.Y955C mutation in POLG1. The clinical features of parkinsonism related to the Y955C mutation in a total of 16 patients, including our two cases, are indistinguishable from iPD. However, neuromelanin MRI showed a distinct pattern in our cases compared to iPD. The neuromelanin imaging results were consistent with the neuropathological findings reported in cases of POLG1 mutations, in which neurons of the SN were profoundly affected while those in the LC were preserved.
CONCLUSIONS: Our results suggest that 3-T neuromelanin MRI may be useful for differentiating POLG1 mutation-associated parkinsonism from iPD, and that POLG1 mutations may cause selective neuronal loss in the SN via a mechanism different from that of iPD.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Mitochondrial DNA; Neuromelanin imaging; POLG1; Parkinsonism; Progressive external ophthalmoplegia

Mesh:

Substances:

Year:  2013        PMID: 23673011     DOI: 10.1016/j.parkreldis.2013.04.011

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  7 in total

1.  A multicontrast approach for comprehensive imaging of substantia nigra.

Authors:  Jason Langley; Daniel E Huddleston; Xiangchuan Chen; Jan Sedlacik; Nishant Zachariah; Xiaoping Hu
Journal:  Neuroimage       Date:  2015-02-28       Impact factor: 6.556

2.  POLG R964C and GBA L444P mutations in familial Parkinson's disease: Case report and literature review.

Authors:  Pei-Chen Hsieh; Chun-Chieh Wang; Chia-Lung Tsai; Yuan-Ming Yeh; Yun Shien Lee; Yih-Ru Wu
Journal:  Brain Behav       Date:  2019-04-02       Impact factor: 2.708

3.  Life span pigmentation changes of the substantia nigra detected by neuromelanin-sensitive MRI.

Authors:  Yue Xing; Abdul Sapuan; Rob A Dineen; Dorothee P Auer
Journal:  Mov Disord       Date:  2018-11-13       Impact factor: 10.338

4.  Midbrain atrophy related to parkinsonism in a non-coding repeat expansion disorder: five cases of spinocerebellar ataxia type 31 with nigrostriatal dopaminergic dysfunction.

Authors:  Ryohei Norioka; Keizo Sugaya; Aki Murayama; Tomoya Kawazoe; Shinsuke Tobisawa; Akihiro Kawata; Kazushi Takahashi
Journal:  Cerebellum Ataxias       Date:  2021-03-30

5.  Neuromelanin-sensitive magnetic resonance imaging: a promising technique for depicting tissue characteristics containing neuromelanin.

Authors:  Ken Nakamura; Keizo Sugaya
Journal:  Neural Regen Res       Date:  2014-04-01       Impact factor: 5.135

Review 6.  Noradrenergic Dysfunction in Alzheimer's and Parkinson's Diseases-An Overview of Imaging Studies.

Authors:  Andrew C Peterson; Chiang-Shan R Li
Journal:  Front Aging Neurosci       Date:  2018-05-01       Impact factor: 5.750

7.  Lower Locus Coeruleus MRI intensity in patients with late-life major depression.

Authors:  Andrés Guinea-Izquierdo; Mónica Giménez; Ignacio Martínez-Zalacaín; Inés Del Cerro; Pol Canal-Noguer; Gerard Blasco; Jordi Gascón; Ramon Reñé; Inmaculada Rico; Angels Camins; Carlos Aguilera; Mikel Urretavizcaya; Isidre Ferrer; José Manuel Menchón; Virginia Soria; Carles Soriano-Mas
Journal:  PeerJ       Date:  2021-02-16       Impact factor: 2.984

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.